Based on previous evidence, we chose AS-IV and LIG as promising drug candidates and hypothesized that they could exert their therapeutic effects by regulating the NOX4-ROS-p38 MAPK and NOX4-NLRP3 pathways to treat and prevent IPF. The gene discussed is NLRP3; the disease is idiopathic pulmonary fibrosis.